AIMS: To investigate the expression of two cell cycle related antigens (proliferating cell nuclear antigen (PCNA) and Ki67 related antigen) in a series of breast cancers; and the possible correlations between the PCNA and Ki67 labelling indexes (PCNA-LI and Ki67-LI) and their associations with other biological and clinicopathological variables. METHODS: Ninety six ductal and 10 lobular carcinoma specimens were investigated. Samples were fixed in formalin and in Methacarnoy for localisation of PCNA. Ki67 was immunostained on frozen sections. The PCNA-LI and Ki67-LI were evaluated in relation to tumour size, mitotic count, histological grade, nodal state as well as receptor content and altered expression of the p53 gene. RESULTS: PCNA-LI did not correlate with Ki67-LI, nor was it associated with any other variable examined. A high KI67-LI (above the median value of 13.5) was associated with high grade and mitotic count, negative receptor content, and altered expression of the p53 gene, but not with other variables. CONCLUSIONS: The PCNA-LI does not seem to be a substitute for the Ki67-LI in evaluating the growth fraction in breast cancer.
AIMS: To investigate the expression of two cell cycle related antigens (proliferating cell nuclear antigen (PCNA) and Ki67 related antigen) in a series of breast cancers; and the possible correlations between the PCNA and Ki67 labelling indexes (PCNA-LI and Ki67-LI) and their associations with other biological and clinicopathological variables. METHODS: Ninety six ductal and 10 lobular carcinoma specimens were investigated. Samples were fixed in formalin and in Methacarnoy for localisation of PCNA. Ki67 was immunostained on frozen sections. The PCNA-LI and Ki67-LI were evaluated in relation to tumour size, mitotic count, histological grade, nodal state as well as receptor content and altered expression of the p53 gene. RESULTS:PCNA-LI did not correlate with Ki67-LI, nor was it associated with any other variable examined. A high KI67-LI (above the median value of 13.5) was associated with high grade and mitotic count, negative receptor content, and altered expression of the p53 gene, but not with other variables. CONCLUSIONS: The PCNA-LI does not seem to be a substitute for the Ki67-LI in evaluating the growth fraction in breast cancer.
Authors: A Allegranza; S Girlando; G L Arrigoni; S Veronese; F A Mauri; M Gambacorta; B Pollo; P Dalla Palma; M Barbareschi Journal: Virchows Arch A Pathol Anat Histopathol Date: 1991
Authors: N R Rodrigues; A Rowan; M E Smith; I B Kerr; W F Bodmer; J V Gannon; D P Lane Journal: Proc Natl Acad Sci U S A Date: 1990-10 Impact factor: 11.205
Authors: H Haneda; M Katabami; H Miyamoto; H Isobe; T Shimizu; A Ishiguro; T Moriuti; Y Takasaki; Y Kawakami Journal: Oncology Date: 1991 Impact factor: 2.935
Authors: P A Hall; D A Levison; A L Woods; C C Yu; D B Kellock; J A Watkins; D M Barnes; C E Gillett; R Camplejohn; R Dover Journal: J Pathol Date: 1990-12 Impact factor: 7.996
Authors: A K Singh; R C Upadhyay; Gulab Chandra; Sudarshan Kumar; D Malakar; S V Singh; M K Singh Journal: Cell Stress Chaperones Date: 2020-02-15 Impact factor: 3.667
Authors: Gertraud Maskarinec; Eva Erber; Martijn Verheus; Brenda Y Hernandez; Jeffrey Killeen; Suzanne Cashin; J Mark Cline Journal: Nutr Cancer Date: 2009 Impact factor: 2.900